NCT03793166 2026-03-18
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
National Cancer Institute (NCI)
Phase 3 Active not recruiting
National Cancer Institute (NCI)
University of Utah
Instituto do Cancer do Estado de São Paulo
Karolinska Institutet
Haraldsplass Deaconess Hospital
Fujian Medical University